Better Therapeutics Completes Enrollment In Real-World Evidence Program Evaluating Long-Term Effectiveness Of AspyreRx In Type 2 Diabetes
Portfolio Pulse from Benzinga Newsdesk
Better Therapeutics (NASDAQ:BTTX) has completed the enrollment of 1,000 participants across two studies for its ongoing clinical program to evaluate the long-term effectiveness of AspyreRx, a prescription digital therapeutic (PDT) for type 2 diabetes. The studies will assess the impact on medication use and healthcare utilization one year after beginning treatment with AspyreRx. The company plans to share initial 6-month data by the end of 2023 and expects AspyreRx to be commercially available in Q4 of this year.
September 28, 2023 | 8:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Better Therapeutics has completed enrollment for its AspyreRx studies, with initial data expected by the end of 2023. The company's confidence in the commercial availability of AspyreRx in Q4 could potentially boost investor confidence.
The completion of enrollment for the AspyreRx studies is a significant milestone for Better Therapeutics. The company's confidence in the commercial availability of AspyreRx in Q4 indicates progress in its product pipeline, which could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100